Vaccine for preventing and treating porcine progressive atrophic rhinitis

Abstract

The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragments of recombinant subunit Pasteurella multocida toxins (rsPMT) capable of eliciting the production of antibodies against. Pasteurella multocida associated with PAR, said fragments each having an amino acid sequence that substantially corresponds to the 2-486, 486-986 or 986-1281 amino acid residues of Pasteurella multocida toxin (PMT), respectively. Also disclosed is a multivalent animal vaccine, comprising said fragments as active components against PAR, and at least a pathogenic antigen or epitope thereof associated with other animal disease(s), such as inactivated gE-deleted Pseudorabies virus.

1 . A multivalent vaccine against progressive atrophic rhinitis (PAR), comprising:
 (i) as the first component a combination of either recombinant  Pasteurella multocida  toxin (rPMT) subunits having an amino acid sequence corresponding to the 2-486 and 986-1281 amino acid residues, or to the 486-986 and 986-1281 amino acid residues, or to the 2-486, 486-986 and 986-1281 amino acid residues in SEQ ID NO: 2 respectively, and   (ii) as the second component at least one antigen or epitope associated with another animal pathology.   
     
     
         2 . The multivalent vaccine of  claim 1 , which comprises inactivated gE-deleted Pseudorabies virus as the second component. 
     
     
         3 . The multivalent vaccine of  claim 1 , which further comprises at least one antigen derived from PMT toxoid,  Pasteurella multocida  serotype A,  Pasteurella multocida  serotype D or  Bordetella bronchiseptica.    
     
     
         4 . The multivalent vaccine of  claim 1 , which further comprises at least one adjuvant selected from Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum gel, oily adjuvant (W/O/W) water-in-oil (W/O) emulsion, oil-in-water (O/W) emulsion, Con A, β-glucosan, and combination thereof. 
     
     
         5 . The multivalent vaccine of  claim 1 , wherein the PMT subunits are derived from  Pasteurella multocida  serotype D isolate. 
     
     
         6 . The multivalent vaccine of  claim 1 , wherein the PMT subunits and the PR are produced by recombinant DNA technology.